Yusha Sun

Yusha Sun

Auto-generated profile, based on publicly available information

Yusha Sun

Neuroscience Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2025 in Nature
Verified
Journal Article
Closed access
PDF file
YSYusha Sun
Yusha Sun
XWXin Wang
Xin Wang
DZDaniel Y. Zhang
Daniel Y. Zhang
ZZZhijian Zhang
Zhijian Zhang
JBJanardhan P. Bhattarai
Janardhan P. Bhattarai
HSHongjun Song
Hongjun Song

25 November 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JXJason Xu
Jason Xu
CCChangya Chen
Changya Chen
JSJonathan H. Sussman
Jonathan H. Sussman
SYSatoshi Yoshimura
Satoshi Yoshimura
TVTiffaney Vincent
Tiffaney Vincent
DTDavid Trent Teachey
David Trent Teachey
Refractoriness to initial chemotherapy and relapse after remission are the main obstacles to curing T cell acute lymphoblastic leukemia (T-ALL). While tumor heterogeneity has been implicated in treatment failure, the cellular and genetic factors contributing to resistance and relapse remain unknown. Here we linked tumor subpopulations with clinical outcome, created an atlas of healthy pediatric hematopoiesis and applied single-cell multiomic analysis to a diverse cohort of 40 T-ALL cases. We identified a bone marrow progenitor (BMP)-like leukemia subpopulation associated with treatment failure and poor overall survival. The single-cell-derived molecular signature of BMP-like blasts predicted poor outcome across multiple subtypes of T-ALL and revealed that NOTCH1 mutations additively drive T-ALL blasts away from the BMP-like state. Through in silico and in vitro drug screenings, we identified a therapeutic vulnerability of BMP-like blasts to apoptosis-inducing agents including venetoclax. Collectively, our study establishes multiomic signatures for rapid risk stratification and targeted treatment of high-risk T-ALL.

5 June 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
YSYusha Sun
Yusha Sun
CBCavan P. Bailey
Cavan P. Bailey
ZSZsila Sadighi
Zsila Sadighi
WZWafik Zaky
Wafik Zaky
JCJoya Chandra
Joya Chandra

18 June 2020 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
KLKe-Chih Lin
Ke-Chih Lin
YSYusha Sun
Yusha Sun
GTGonzalo Torga
Gonzalo Torga
PSPema Sherpa
Pema Sherpa
YZYihua Zhao
Yihua Zhao
RARobert Austin
Robert Austin
The heterogenous, highly metabolic stressed, poorly irrigated, solid tumor microenvironment – the tumor swamp – is widely recognized to play an important role in cancer progression as well as the development of therapeutic resistance. It is thus important to create realistic in vitro models within the therapeutic pipeline that can recapitulate the fundamental stress features of the tumor swamp. Here we describe a microfluidic system which generates a chemical gradient within connected microenvironments achieved through a static diffusion mechanism rather than active pumping. We show that the gradient can be stably maintained for over a week. Due to the accessibility and simplicity of the experimental platform, the system allows for not only well-controlled continuous studies of the interactions among various cell types at single-cell resolution, but also parallel experimentation for time-resolved downstream cellular assays on the time scale of weeks. This approach enables simple, compact implementation and is compatible with existing 6-well imaging technology for simultaneous experiments. As a proof-of-concept, we report the co-culture of a human bone marrow stromal cell line and a bone-metastatic prostate cancer cell line using the presented device, revealing on the same chip a transition in cancer cell survival as a function of drug concentration on the population level while exhibiting an enrichment of poly-aneuploid cancer cells (PACCs) as an evolutionary consequence of high stress. The device allows for the quantitative study of cancer cell dynamics on a stress landscape by real-time monitoring of various cell types with considerable experimental throughput.

21 April 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
CHChristopher G Hubert
Christopher G Hubert
RRRenee D Read
Renee D Read
TMTyler E Miller
Tyler E Miller
UKUijin Kim
Uijin Kim
XWXin Wang
Xin Wang
ZWZhaohui Wang
Zhaohui Wang
Advances in organoid technology have transformed how gliomas are modeled and studied. Recent FDA and NIH initiatives further promote human-relevant organoid platforms for preclinical research. Glioma organoids can be broadly categorized into 3 main classes: Engineered organoids, which enable controlled modeling of gliomagenesis driven by specific mutations; patient-derived organoids, which preserve key molecular and histopathological features of the original tumors; and assembloids, which are designed to model tumor-microenvironment interactions. Together, these systems provide a human cell-relevant framework for investigating glioma biology, tumor-microenvironment crosstalk, and therapeutic responses and resistance. In this review, we provide a comprehensive overview of the spectrum of glioma organoid models, recognizing that different systems offer distinct and complementary strengths, and we offer practical guidance for selecting appropriate models and analytical readouts based on specific basic and translational research objectives. To address increasing methodological heterogeneity and fragmented terminology, we propose a foundational nomenclature framework for glioma organoid models to improve clarity and communication within the field. We highlight applications in technically challenging subtypes, including isocitrate dehydrogenase (IDH)-mutant gliomas and diffuse midline gliomas (DMGs). We also discuss key challenges—including scalability, standardization, microenvironment fidelity, and vascularization—and emerging innovations addressing these limitations. Finally, we call for greater collaboration and standardization within the glioma organoid community to accelerate the integration of organoid models into translational pipelines to redefine and refine preclinical modeling in neuro-oncology.

21 January 2026 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
YSYusha Sun
Yusha Sun
XWXin Wang
Xin Wang
ZZZhijian Zhang
Zhijian Zhang
GMGuo-li Ming
Guo-li Ming
HSHongjun Song
Hongjun Song